# innovaTV 301 (NCT04697628)

> Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04697628
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: Cervical Cancer
- Interventions: tisotumab vedotin; topotecan; vinorelbine; gemcitabine; irinotecan; pemetrexed
- Enrollment: 502
- Primary outcome: Overall Survival

## Commentary we found

- Podcasts: 14
- YouTube: 13
- X threads: 6

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=innovatv-301-nct04697628

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04697628", "email": "<work email>"}; the inbox owner confirms by the emailed link.